Three new studies identify neutralizing antibodies against SARS-CoV-2

June 15, 2020

A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection. Several of these antibodies showed protective, neutralizing capabilities, offering promising therapeutic leads, and eight antibodies from one analysis were discovered to cross-react with a related bat-specific coronavirus - with implications for the identification of broadly neutralizing antibodies to protect against potential new coronavirus outbreaks in the future. Philip Brouwer and colleagues isolated 403 monoclonal antibodies from 3 convalescent COVID-19 patients, showing that the patients had strong immune responses against the viral spike, a protein complex that binds to the ACE2 receptor to facilitate entry into human host cells. A subset of these antibodies neutralized the virus by targeting diverse epitopes on the spike, with the two most potent ones targeting the domain that binds the host receptor. In another study, Thomas Rogers and colleagues used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors, selecting for antibodies that bind to the viral spike. Several of the isolated antibodies bound to the receptor binding domain (RBD) and demonstrated neutralizing capabilities, with the most potent ones binding at a site that overlaps the ACE2 binding site. Two of these neutralizing antibodies gave protection against SARS-CoV-2 infection when tested in Syrian hamsters. In a third study to identify broadly protective, cross-reactive antibodies, Anna Wec and colleagues isolated and characterized hundreds of antibodies against the viral spike of SARS-CoV-2 from the memory B cells of a SARS-CoV survivor. Both of these closely related viruses rely on the spike to gain host cell entry by binding the ACE2 receptor. Of nine antibodies that showed strong cross-neutralization of both viruses, eight target the domain that binds the ACE2 receptor - and also neutralized a closely related species of bat coronavirus. Taken together, the trio of studies offers several new human antibodies to help inform the design of therapeutic antibody drugs and vaccines against SARS-CoV-2, as well as the design of broadly protective vaccines against a range of related coronaviruses.

American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to